Track: Basic Science

Abstract:

Background: Lymphomatoid papulosis (LyP) is a cutaneous CD30-positive lymphoproliferative disorder characterized by recurrent, self-regressing papulonodular eruptions. Despite its indolent behavior, approximately 20% of cases progress to systemic lymphoid malignancies, particularly when clonal T-cell receptor (TCR) gene rearrangements are present. TRBC1, a marker of the TCR β-chain constant region, has been validated for clonality assessment in flow cytometry and molecular assays. Immunohistochemistry (IHC) for TRBC1 is a cost-effective alternative, but its diagnostic utility in LyP is not well defined. Design: We retrospectively identified biopsy-proven LyP cases (2020–2025) from our institutional archives. Formalin-fixed paraffin-embedded tissue was reviewed, and IHC for CD3 and TRBC1 was performed. TRBC1 expression was quantified as the percentage of CD3+ T-cells. Clonality was defined as monoclonal if >85% or <15% of CD3+ T-cells expressed TRBC1, and polyclonal if expression was between 15–85%. A binomial test evaluated whether the proportion of monoclonal cases differed from a null expectation of 50%. Result: Twenty-seven LyP cases were included. TRBC1 IHC demonstrated monoclonal T-cell populations in 22 cases (81.5%) and polyclonal expression in 5 cases (18.5%). The monoclonality rate was significantly greater than expected by chance (p < 0.01). Conclusion: TRBC1 IHC is a valuable adjunct for detecting T-cell clonality in LyP. It provides a rapid, inexpensive, and widely available alternative to molecular testing. Incorporating TRBC1 IHC into routine diagnostic workflows may improve diagnostic confidence and aid in risk stratification for patients with LyP.

Sarah Merl

Affiliation

Refine Results

(189) Utility of TRBC1 Immunohistochemistry (IHC) as an Adjunct Tool for Assessing T-Cell Clonality in Lymphomatoid Papulosis.